Hepatocellular Carcinoma

Adenoviral Vectors Deliver Potent Killer to Cancer Cells

Published in Gene Therapy Weekly, May 4th, 2000

Researchers at Brown University have demonstrated that adenoviral vectors can facilitate the delivery of an Escherichia coli purine nucleoside phosphorylase (PNP)/fludarabine system in mice that shows potential for treating hepatocellular carcinoma (HCC).

According to L. Mohr and colleagues at Brown, "The E. coli purine nucleoside phosphorylase (PNP) converts purine analogs into freely diffusible metabolites, which are highly toxic to dividing and nondividing cells."

Investigators analyzed the effect of PNP in three cell HCC cell lines: HepG2, Hep3B, and HuH-7. PNP effects were compared with the effect of using herpes simplex...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2000-05-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry